-

Shareholder Alert: Robbins LLP is Investigating Splunk, Inc. (SPLK) on Behalf of Shareholders

SAN DIEGO & SAN FRANCISCO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating Splunk, Inc. (NASDAQ: SPLK) on behalf of shareholders to determine whether certain Splunk officers and directors violated the Securities Exchange Act of 1934 and breached their fiduciary duties to the Company. Splunk develops and markets software solutions that enable organizations to gain real-time organizational intelligence in the U.S. and internationally.

If you suffered a loss due to Splunk Inc.'s misconduct, click here.

Splunk, Inc. (SPLK) Misled Shareholders About its Third Quarter 2021 Financial Results

On October 21, 2020, Splunk held a call with several analysts at the Virtual Analyst & Investor Session at .conf20. During the call, Splunk assured investors that everything was on track for its third quarter 2021 financial results. However, after the markets closed on December 2, 2020, Splunk announced disappointing results for its third quarter 2021, including an 11% decrease in total revenues, which missed estimates by nearly $60 million. On an earnings call the same day, Splunk admitted that despite reiterating its 2021 third quarter guidance just 10 days before the close of the quarter, the results fell "short of both our expectation and our communication of those expectations." On this news, JPMorgan announced it was "blindsided by the magnitude of too many large details slipping in the final days of October." Shares of Splunk plummeted, closing down over 24% on December 3, 2020. Shareholders later learned that Splunk had failed to disclose it was not closing deals with its largest customers and was not hitting the financial targets it had previously announced.

Splunk, Inc. (SPLK) Shareholders Have Options

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Splunk, Inc. settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Robbins LLP Reminds DRVN Stockholders of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About the Class Action Against Driven Brands Holdings Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Driven Brands Holdings Inc. (NASDAQ: DRVN) common stock between May 9, 2023 and February 24, 2026. Driven Brands is the largest automotive services company in North America, operating in approximately 4,900 locations across more than 15 countries. The Company provides maintenance, car wash, collision, and glass services, and operates as a holdi...

Investor Notice: Robbins LLP Informs Investors of the FS KKR Capital Corp. Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired FS KKR Capital (NYSE: FSK) securities between May 8, 2024 and February 25, 2026. FS KKR Capital is a private credit firm, also known as Business Development Company, which specializes in making private loans to companies.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Ro...

Robbins LLP Urges GOSS Stockholders to Contact the Firm for Information About the Class Action Against Gossamer Bio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gossamer Bio, Inc. (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026. Gossamer is a clinical stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension (PH) associated with interstitial lung disease.For more information, submit a form, email att...
Back to Newsroom